Figure 3. Time to Confirmed Disability Progression for at Least 12 Weeks.

Figure 3Time to Confirmed Disability Progression for at Least 12 Weeks

Adj. = adjusted; CDP = confirmed disability progression; CI = confidence interval; EDSS = Expanded Disability Status Scale; HR = hazard ratio; ITT = intention-to-treat population; GdE = gadolinium-enhancing; OCR = ocrelizumab; n = number of patients with an event; N = number of patients in the analysis; NA = not applicable; pts = patients; vs. = versus; WD = withdrawal.

Source: Clinical Study Report for ORATORIO.1

From: Results

Cover of Clinical Review Report: Ocrelizumab (Ocrevus)
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Management of adult patients with early primary progressive multiple sclerosis as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity [Internet].
Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.